The Emerging Landscape of Respiratory Viral Infections in Immunocompromised Children
Cancers · 24.02.2026 · 18 (5) · 725
DOI: 10.3390/cancers18050725 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 24.02.2026. Verfasst von Paschalis Evangelidis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Second Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Respiratory viral infections (RVIs) have been described traditionally as clinically important infectious complications in pediatric patients with immunosuppression, particularly in those with malignancies (hematological or solid) and recipients of hematopoietic cell or solid organ transplantation. Specifically, advances in the field of cancer therapy and novel immune-based pharmaceuticals have significantly expanded the population of children with prolonged and complex immunosuppression, whereas the widespread use and availability of molecular diagnostics have increased the detection of respiratory viruses. Additionally, these developments have improved the etiologic identification of RVIs, while introducing important challenges in clinical interpretation, mainly in differentiating incidental viral identification from clinically significant diseases. Furthermore, RVIs in immunocompromised children are characterized by heterogeneous and diverse clinical manifestations, with a range from mild upper respiratory tract involvement to severe lower respiratory tract disease, which can lead to substantial morbidity and mortality. Diagnostic strategies in this field are primarily based on nucleic acid amplification tests, requiring careful interpretation because of the possible prolonged viral shedding, co-detection, and overlapping infectious syndromes. Beyond direct clinical consequences, viral detection has an impact on infection control measures, antimicrobial stewardship decisions, and the timing of therapies. In this literature review, we offer an overview of current evidence on the epidemiology, clinical manifestations, diagnostic approaches, and management of RVIs in immunocompromised pediatric populations, underscoring the unmet need for structured, risk-adapted integration of virologic data into pediatric oncology care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Second Propedeutic Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
- Third Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Hippokration General Hospital, 54642 Thessaloniki, Greece.
- Children & Adolescent Hematology-Oncology Unit, Second Department of Pediatrics, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
ORCID-Profile: Paschalis Evangelidis, Elias Iosifidis, Athanasios Tragiannidis, Emmanouel Hatzipantelis, Emmanuel Roilides, Maria Kourti
Zitieren
APA
Evangelidis, P., Iosifidis, E., Tragiannidis, A., Hatzipantelis, E., Roilides, E., & Kourti, M. (2026). The Emerging Landscape of Respiratory Viral Infections in Immunocompromised Children. Cancers, 18(5), 725. https://doi.org/10.3390/cancers18050725
Vancouver
Evangelidis P, Iosifidis E, Tragiannidis A, Hatzipantelis E, Roilides E, Kourti M. The Emerging Landscape of Respiratory Viral Infections in Immunocompromised Children. Cancers. 2026;18(5):725. doi:10.3390/cancers18050725
BibTeX
@article{Evangelidis2026,
author = {Evangelidis, Paschalis and Iosifidis, Elias and Tragiannidis, Athanasios and Hatzipantelis, Emmanouel and Roilides, Emmanuel and Kourti, Maria},
title = {The Emerging Landscape of Respiratory Viral Infections in Immunocompromised Children},
journal = {Cancers},
year = {2026},
volume = {18},
number = {5},
pages = {725},
doi = {10.3390/cancers18050725}
}
EUVIMED